EconomyAkeso shares plunge after FDA setback for cancer drug ivonescimab
Shares in Hong Kong-listed Akeso fell as much as 31.8 per cent on Monday morning after the FDA rejected its application for cancer drug ivonescimab, prompting investor concerns about the company’s near-term commercial outlook.
Akeso shares plunge after FDA setback for cancer drug ivonescimab
Economy